Drugs / Simtuzumab
Trials 13 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01362231 | Dec 2010 → Dec 2012 | idiopathic pulmonary fibrosis | Gilead Sciences | Completed | No outcome recorded |
| Phase 1 | NCT01323933 | Jun 2010 → Mar 2012 | neoplasm | Gilead Sciences | Completed | No outcome recorded |
| Phase 211 trials | ||||||
| Phase 2 | NCT02466516 | Jun 2015 → Oct 2016 | metabolic dysfunction-associated steatohepatitis | Gilead Sciences | Completed | No outcome recorded |
| Phase 2 | NCT01672853 | Mar 2013 → Aug 2016 | primary sclerosing cholangitis | Gilead Sciences | Completed | No outcome recorded |
| Phase 2 | NCT01769196 | Jan 2013 → Feb 2016 | idiopathic pulmonary fibrosis | Gilead Sciences | Terminated | No outcome recorded |
| Phase 2 | NCT01672866 | Dec 2012 → Aug 2016 | fibrotic liver disease | Gilead Sciences | Terminated | No outcome recorded |
| Phase 2 | NCT01672879 | Oct 2012 → Sep 2016 | metabolic dysfunction-associated steatohepatitis | Gilead Sciences | Terminated | No outcome recorded |
| Phase 2 | NCT01759511 | Oct 2012 → Feb 2016 | idiopathic pulmonary fibrosis | Gilead Sciences | Terminated | No outcome recorded |
| Phase 2 | NCT01707472 | Oct 2012 → Oct 2014 | HIV infectious disease, fibrotic liver disease, hepatitis C virus infection | Gilead Sciences | Completed | No outcome recorded |
| Phase 2 | NCT01479465 | Dec 2011 → Oct 2014 | colorectal cancer | Gilead Sciences | Terminated | No outcome recorded |
| Phase 2 | NCT01452308 | Nov 2011 → Jan 2013 | fibrotic liver disease | Gilead Sciences | Completed | No outcome recorded |
| Phase 2 | NCT01472198 | Nov 2011 → Oct 2013 | malignant pancreatic neoplasm | Gilead Sciences | Completed | No outcome recorded |
| Phase 2 | NCT01369498 | Jun 2011 → Jun 2014 | myelofibrosis | Gilead Sciences | Completed | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2016-01-05 | Gilead Sciences | Gilead Terminates Phase 2 Study of Simtuzumab in Patients With Idiopathic Pulmonary Fibrosis gilead.com ↗ |
| 2014-09-17 | Gilead Sciences | Gilead Announces Data From Phase 2 Study of Simtuzumab for Previously Untreated Pancreatic Cancer gilead.com ↗ |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 15 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Simtuzumab | “We evaluated the safety and efficacy of simtuzumab, a monoclonal antibody against lysyl oxidase-like 2, in two phase 2b trials of patients with advanced fibrosis caused by...” PMID 29990488 ↗ Jul 201810“Safety and Efficacy of Simtuzumab (SIM, GS-6624) in Adults With Advanced Liver Fibrosis But Not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH)” NCT01672866 ↗ “Simtuzumab (SIM) 125 mg/mL single-dose vials administered subcutaneously once weekly” NCT02466516 ↗ |
| Known as | AB0024 | “A Study to Evaluate the Safety and Efficacy of GS-6624 (Formerly AB0024) in Patients With Idiopathic Pulmonary Fibrosis” NCT01362231 ↗ |
| Known as | GS-6624 | “This study will evaluate the safety and tolerability of simtuzumab (GS-6624) in patients with fibrosis of the liver.” NCT01452308 ↗ |
| Known as | SIM | “Safety and Efficacy of Simtuzumab (SIM, GS-6624) in Adults With Advanced Liver Fibrosis But Not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH)” NCT01672866 ↗1“Simtuzumab (SIM) 125 mg/mL single-dose vials administered subcutaneously once weekly” NCT02466516 ↗ |
| Action | Inhibit | “simtuzumab inhibits the extracellular matrix-remodeling enzyme lysyl oxidase-like 2” PMID 28246206 ↗ Feb 2017 |
| Modality | Monoclonal antibody | “The humanized IgG4 monoclonal antibody simtuzumab inhibits the extracellular matrix-remodeling enzyme lysyl oxidase-like 2 maintaining pathological stroma in tumors.” PMID 28246206 ↗ Feb 2017 |
| Route | Intravenous | “after multiple IV administrations” NCT01323933 ↗ |
| Target | LOXL2 | “a monoclonal antibody directed against LOXL2” PMID 30153359 ↗ Jan 2019 |